Results 111 to 120 of about 2,560 (200)
Type‐I photodynamic therapy (PDT) agents offer a promising approach for treating hypoxic tumors. However, previous reports mainly focused on thermodynamic modulation through molecular engineering to block the Type‐II energy transfer pathway.
Minglu Zhang +14 more
doaj +1 more source
Background: Seasonal influenza causes significant morbidity and mortality each year. Since viruses can easily acquire drug-resistant mutations, it is necessary to develop new antiviral strategies with different targets.
Koichiro Tateishi +6 more
core +1 more source
Monoclonal antibodies and cancer: photoimmunotherapy and radioimmunoimagery
The advantage of using monoclonal antibodies in the treatment of malignancies lies in its potential to make cancer therapy or detection more tumour specific.
Mew, Daphne Jung Yen
core +1 more source
Reducing the immunosuppressive tumor microenvironment enhances photoimmunotherapy efficacy
Mouldy Sioud
doaj +1 more source
Cancer progression and treatment-associated cellular stress impairs therapeutic outcome by inducing resistance. Endoplasmic reticulum (ER) stress is responsible for core events.
Jiajia Li (184267) +13 more
core +1 more source
Enhanced nanodrug delivery in tumors after near-infrared photoimmunotherapy
To date, the delivery of nanosized therapeutic agents to cancers largely relies on the enhanced permeability and retention (EPR) effects that are caused by the leaky nature of cancer vasculature. Whereas leaky vessels are often found in mouse xenografts,
Kobayashi Hisataka +7 more
core +1 more source
Lipid‐mediated phase separation is crucial for the formation of lipophilic spontaneous domain to regulate lipid metabolism and homeostasis, furtherly contributing to multiple cell death pathways.
Yue Zheng +8 more
doaj +1 more source
Bacterial outer membrane vesicles (OMVs) are promising as antitumour agents, but their clinical application is limited by toxicity concerns and unclear mechanisms.
Peng Xia +13 more
doaj +1 more source
Mechanism of Action--Photoimmunotherapy
A slide deck presenting photoimmunotherapy (PIT) as a novel therapeutic modality combining the target precision of monoclonal antibodies with localize activation by near-infrared (NIR) light. Antibody-photoabsorber conjugates, incorporating the dye IRDye700DX, selectively bind tumor-associated antigens such as EGFR or HER2. Once illuminated with 690 nm
openaire +1 more source
Background: Advanced epithelial ovarian cancer (EOC) has high recurrence rates due to disseminated initial disease presentation. Cytotoxic phototherapies, such as photodynamic therapy (PDT) and photoimmunotherapy (PIT, cell-targeted PDT), have the ...
Waguespack, Matthew +8 more
core +1 more source

